My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}
AlphaStreet

Want to join the conversation?


$TRV {{ '2015-06-24T18:10:37+0000' | timeago}} • SEC

$TRV 1Q15 10-Q: At March 31, 2015 (vs. at Dec. 31, 2014): Total assets were $102,691MM vs. $103,078MM. Total liabilities were $77,844MM vs. $78,242MM. Total investments were $72,619MM vs. $73,261MM. Book value per common share was $77.96. Holding company liquidity was $1.71Bil. Carrying value of the fixed maturity portfolio was $62.77Bil.

User John Yono {{ '2016-12-02T20:09:52+0000' | timeago}}

$DB is going to cut off services for about 3,400 clients in equities trading.

User Suzie Merlin {{ '2016-12-02T19:28:37+0000' | timeago}}

$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.

User Melwyn Jones {{ '2016-12-02T17:58:55+0000' | timeago}}

The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.

User Nick Velez {{ '2016-12-02T17:15:02+0000' | timeago}}

U.S. unemployment rate fell to a 9-year low in November to 4.6% from 4.9% in October. This was due to the addition of 178,000 new jobs in the month, according to the Labor Department report.

User Godfrey Russell {{ '2016-12-02T17:00:15+0000' | timeago}}

$TSLA opening a showroom in Michigan. A bold move !!

$LDOS {{ '2016-12-05T12:34:42+0000' | timeago}} • Announcement

$LDOS's BoD declared a quarterly cash dividend of $0.32 per outstanding share of common stock. The dividend is payable on Dec. 30, 2016 to stockholders of record on Dec. 15, 2016.

$ABBV {{ '2016-12-05T12:32:44+0000' | timeago}} • Announcement

$ABBV announced efficacy and safety findings from two separate studies evaluating ibrutinib as a combination therapy in two of the most common types of non-Hodgkin's lymphoma: diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Preliminary efficacy results demonstrated highest response rate was observed in patients.

$ALXN {{ '2016-12-05T12:28:19+0000' | timeago}} • Announcement

$ALXN said new data from ALXN1210 dose-escalation study were presented at ASH. This showed rapid and sustained reductions in lactate dehydrogenase (LDH), a direct marker of hemolysis (the destruction of red blood cells), in patients with paroxysmal nocturnal hemoglobinuria (PNH).

$THC {{ '2016-12-05T12:25:34+0000' | timeago}} • Announcement

$THC and $UNH renewed national relationship for four years. This ensures all $UNH commercial and Medicare Advantage plan participants have continued in-network access to $THC's hospitals, outpatient centers and employed physicians across the country.

$PFE {{ '2016-12-05T12:19:37+0000' | timeago}} • Announcement

$PFE said the new Phase 2 study showed investigational compound glasdegib improved overall survival in acute myeloid leukemia and high-risk myelodysplastic syndrome. The data on first smoothened inhibitor to show clinical benefit in this patient population to be presented during oral session at 2016 ASH Annual Meeting.